touchIMMUNOLOGY caught up with Dr Emanuel Della Torre (Università Vita-Salute San Raffaele Unit of Immunology, Rheumatology, Allergy, and Rare Diseases, Ospedale San Raffael, Milan, Italy) to discuss the current and future treatment of immunoglobulin G4-related (IgG4) diseases.
His presentation entitled ‘Management: current therapy of IgG4-related systemic disease and what is on the horizon‘ was given at EASL ILC 2021, 23-26 June.
Questions
- What factors should be considered when treating patients with IgG4-mediated systemic disease? (0:18)
- How common is relapse following glucocorticoid treatment and what are the predictors of relapse? (1:39)
- What are the indications for and treatment goals of immunosuppressive treatment? (2:26)
- What have we learned about the clinical utility of mycophenolate mofetil and B-cell targeted therapy in this treatment setting? (4:06)
- What novel therapeutic approaches are on the horizon? (5:31)
Disclosures: Dr Emanuel Della Torre has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival.
Filmed in coverage of the EASL ILC 2021, 23-26 June.
